🤖 GLOBAL HEALTH OPTIMIZATION AGENT v3.0

🔬 Current Disease Focus:

Task Progress: 0%

👥 Active Problem Solvers

🌍 Experts collaborating globally

⚡ Current Task Assignment

🧬 Genetic Analysis

🔄 Matching experts to specific tasks

📊 Resource Allocation by Research Phase:

📚 Data Analysis

🧪 Experimental Design

🔬 Clinical Trials

💊 Treatment Development

Trial Search

Current Search Criteria:

Intervention: GSK2982772

Found 9 matching trials

A Safety and Tolerability Study of GSK2982772, in Single (in Both Fed and Fasted States) and Repeat Oral Doses in Healthy Male Subjects

PHASE1

This study is the first administration of GSK2982772 in humans. The study w...

Status

Completed

Location

GSK Investigational Site

Start Date

2015-01-06

Trial ID

NCT02302404

Treatments Being Tested

GSK2982772 solution GSK2982772 capsule Placebo solution Placebo capsule

A Safety and Pharmacokinetic (PK) Study of GSK2982772 in Healthy Subjects

PHASE1

This study is designed to evaluate the safety, tolerability and PK of GSK29...

Status

Completed

Location

GSK Investigational Site

Start Date

2017-10-11

Trial ID

NCT03305419

Treatments Being Tested

GSK2982772 capsule Placebo capsule

A Study to Compare the Pharmacokinetics (PK) of GSK2982772 Following Administration of Different Modified Release (MR) Formulations in Capsule and MR Tablet Formulations Relative to an Immediate Release (IR) Tablet Formulation and to Check the PK of MR Formulation in Capsule Following Repeat Doses

PHASE1

GSK2982772 is a first-in-class, highly selective, receptor-interacting prot...

Status

Completed

Location

GSK Investigational Site

Start Date

2017-09-27

Trial ID

NCT03266172

Treatments Being Tested

GSK2982772 Modified Release GSK2982772 Immediate Release

A Study to Investigate the Pharmacokinetics (PK) of Modified Release (MR) Prototype Coated Tablet Formulations of GSK2982772

PHASE1

Previous clinical studies of immediate release (IR) formulations of GSK2982...

Status

Completed

Location

GSK Investigational Site

Start Date

2018-09-26

Trial ID

NCT03649412

Treatments Being Tested

GSK2982772 Modified Release GSK2982772 Immediate Release

A Study to Evaluate the Benefit and Safety of GSK2982772 in Moderate to Severe Psoriasis Participants

PHASE1

Plaque psoriasis is a chronic relapsing inflammatory skin disease that is c...

Status

Completed

Location

GSK Investigational Site

Start Date

2020-09-28

Trial ID

NCT04316585

Treatments Being Tested

GSK2982772 Placebo

Phase I Study of GSK2982772 in Japanese Healthy Male Participants

PHASE1

The study plans to enroll approximately 12 subjects. The main objective of ...

Status

Completed

Location

GSK Investigational Site

Start Date

2018-07-19

Trial ID

NCT03590613

Treatments Being Tested

GSK2982772 Placebo

GSK2982772 Study in Subjects With Ulcerative Colitis

PHASE2

This study is the first experience with GSK2982772, a receptor-interacting ...

Status

Completed

Location

GSK Investigational Site

Start Date

2016-11-15

Trial ID

NCT02903966

Treatments Being Tested

GSK2982772 Placebo

Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of Repeat Doses of GSK2982772 in Subjects With Psoriasis

PHASE2

This is the first study with GSK2982772, a receptor-interacting protein-1 (...

Status

Completed

Location

GSK Investigational Site

Start Date

2016-08-30

Trial ID

NCT02776033

Treatments Being Tested

GSK2982772 Placebo

Safety and Tolerability, Pharmacokinetics (PK), Pharmacodynamics (PD) and Efficacy of Repeat Doses of GSK2982772 in Subjects With Moderate to Severe Rheumatoid Arthritis (RA)

PHASE2

This study is the first study with GSK2982772, a receptor-interacting prote...

Status

Completed

Location

GSK Investigational Site

Start Date

2016-10-17

Trial ID

NCT02858492

Treatments Being Tested

GSK2982772 60 mg Placebo

Previous Next